KEY FEATURES
| Full Name | Chemokine C-Motif Ligand 1 |
|---|---|
| Synonym | Lptn; SCYC1; LTN; ATAC; SCM1-A; SCM1a; LPTN; Lymphotactin; Lymphotaxin; Chemokine C-Motif Ligand 1; Small Inducible Cytokine Subfamily C,Member 1; XC chemokine ligand 1 |
| Assay Type | Sandwich |
| Reactivity | Human |
| Range | 15.6-1000pg/mL |
| Sensitivity | 5.6pg/mL |
| Sample Type | Serum,plasma and other biological fluids |
| Sample Volume | 100μL |
| Detection Wavelength | OD450 |
| Transportation Temperature | 2-8°C |
| Specificity | The kit detected Human XCL1 in the samples and no significant cross-species reactions were found |
| Microplate | 96-wells plate breakable into 12 x 8 wells strip |
TEST PRINCIPLE
| This ELISA kit uses the Sandwich-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with an antibody specific to Human XCL1. Standards or samples are added to the micro ELISA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for Human XCL1 and Avidin-Horseradish Peroxidase (HRP) conjugate are added successively to each micro plate well and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Human XCL1, biotinylated detection antibody and Avidin-HRP conjugate will appear blue in color. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The OD value is proportional to the concentration of Human XCL1. You can calculate the concentration of Human XCL1 in the samples by comparing the OD of the samples to the standard curve. |
ELISA KIT COMPONENTS
Upon receipt, unpack promptly and store as recommended in the instructions.
| Components | Specifications | Storage and Notes |
|---|---|---|
| Micro Plate | 96T: 8 wells×12 strips 48T: 8 wells×6 strips | Unopened: -20°C, 12 months Unused: Put it back in the aluminum foil bag and seal it, store it at -20°C. |
| Reference Standard | 96T: 2 vials 48T: 1 vial | Unopened: -20°C, 12 months Please use freshly dissolved standards for each experiment. Discard any unused standards after dissolution. |
| Biotinylated Detection Ab Concentrate (100×) | 96T: 120μL×1 vial 48T: 60μL×1 vial | Unopened: -20°C, 12 months Unused: Please seal the concentrate and store it at -20°C, and discard the working solution. |
| HRP Conjugate Concentrate (100×) | 96T: 120μL×1 vial 48T: 60μL×1 vial | Unopened: -20°C(Protect from light), 12 months Unused: Please seal the concentrate and store it at -20°C, and discard the working solution. |
| Biotinylated Detection Ab Diluent | 14mL×1 | 2-8℃, 12 months |
| HRP Conjugate Diluent | 14mL×1 | 2-8℃, 12 months |
| Reference Standard & Sample Diluent | 20mL×1 | 2-8℃, 12 months |
| Washing Buffer Concentrate (25×) | 30mL×1 | 2-8℃, 12 months |
| Substrate Reagent(TMB) | 10mL×1 | 2-8°C(Protect from light),12 months |
| Stop Solution | 7mL×1 | 2-8°C/Room temperature |
ASSAY PROCEDURES

TYPICAL DATA

Human XCL1 ELISA Standard Curve
Typical data are for reference only and curves should be replotted for each experiment. The Logistics function is recommended for fitting.
PRECISION
Intra-Assay Precision (Precision within an assay): Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): Three samples of known concentration were tested in twenty separate assays to assess inter-assay precision. Assays were performed by at least three technicians using two lots of components.
| Intra-assay Precision | Inter-assay Precision | |||||
|---|---|---|---|---|---|---|
| Sample | 1 | 2 | 3 | 1 | 2 | 3 |
| n | 20 | 20 | 20 | 20 | 20 | 20 |
| Mean (pg/mL) | 51.73 | 137.4 | 433.94 | 48.5 | 131.99 | 403.67 |
| Standard deviation | 3.51 | 7.82 | 16.01 | 2.5 | 5.83 | 18.61 |
| CV(%) | 6.79 | 5.69 | 3.69 | 5.15 | 4.42 | 4.61 |
RECOVERY
The recovery of Human XCL1 spiked to three different levels in samples throughout the range of the assay in various matrices was evaluated.
| Sample Type | Range (%) | Average Recovery (%) |
|---|---|---|
| Serum(n=8) | 91-104 | 99 |
| EDTA plasma (n=8) | 89-104 | 95 |
| Cell culture media (n=8) | 88-103 | 96 |
LINEARITY
To assess the linearity of the assay, samples containing and/or spiked with high concentrations of Human XCL1 in various matrices were diluted with the Reference Standard & Sample Diluent to produce samples with values within the dynamic range of the assay.

Products associated with LTN ELISA Kits
| CD4 ELISA Kit | publications with LTN and CD4 |
| XCR1 ELISA Kit | publications with LTN and XCR1 |
| CXCR3 ELISA Kit | publications with LTN and CXCR3 |
| CCR5 ELISA Kit | publications with LTN and CCR5 |
| CCR1 ELISA Kit | publications with LTN and CCR1 |
| CCR2 ELISA Kit | publications with LTN and CCR2 |
| CX3CR1 ELISA Kit | publications with LTN and CX3CR1 |
| CCR3 ELISA Kit | publications with LTN and CCR3 |
| CCR7 ELISA Kit | publications with LTN and CCR7 |
Pathways associated with LTN ELISA Kit
| Chemokine Receptors Bind Chemokines Pathway | Chemokine Receptors Bind Chemokines Pathway |
| Chemokine Signaling Pathway | Chemokine Signaling Pathway |
| Class A/1 (Rhodopsin-like Receptors) Pathway | Class A/1 (Rhodopsin-like Receptors) Pathway |
| Cytokine-cytokine Receptor Interaction Pathway | Cytokine-cytokine Receptor Interaction Pathway |
| G Alpha (q) Signalling Events Pathway | G Alpha (q) Signalling Events Pathway |
| GPCR Downstream Signaling Pathway | GPCR Downstream Signaling Pathway |
| GPCR Ligand Binding Pathway | GPCR Ligand Binding Pathway |
| Gastrin-CREB Signalling Pathway Via PKC And MAPK | Gastrin-CREB Signalling Pathway Via PKC And MAPK |
Diseases associated with LTN ELISA Kit
| Inflammation | publications with LTN and Inflammation |
| Carcinoma | publications with LTN and Carcinoma |
| Disease Models, Animal | publications with LTN and Disease Models, Animal |
| Necrosis | publications with LTN and Necrosis |
| Neoplasms, Experimental | publications with LTN and Neoplasms, Experimental |
| Nervous System Diseases | publications with LTN and Nervous System Diseases |
| Drug Hypersensitivity | publications with LTN and Drug Hypersensitivity |
| Colonic Neoplasms | publications with LTN and Colonic Neoplasms |
| Eye Diseases | publications with LTN and Eye Diseases |
| Carcinoma, Squamous Cell | publications with LTN and Carcinoma, Squamous Cell |
Organs/Tissues associated with LTN ELISA Kit
| Blood | publications with LTN and Blood |
| Lung | publications with LTN and Lung |
| Liver | publications with LTN and Liver |
| Prostate | publications with LTN and Prostate |
| Connective Tissue | publications with LTN and Connective Tissue |
| Uterus | publications with LTN and Uterus |